Pharma & Bio
Lifestyle
Why ECM Skinbooster Is Maintaining a ‘Two-Track’ Approach to Distribution and Sales
Amid an explosive surge in demand for extracellular matrix (ECM)-based products in the skin booster market, HANS BIOMED CORPORATION(042520)and L&C BIO(290650)—which currently dominate the domestic mar…
Lifestyle
[Bio USA] Jeong In-ki, CEO of GID Partners and “Key Player in the Hanmi Big Deal”: “Big Pharma Was the First to Discover a Cell Therapy for Parkinson’s Disease”
“To be honest, I was skeptical at first. I wondered if a treatment that involves directly implanting cells into the brain of each individual patient was even realistically possible. But after reviewin…
Technology
Lee Soo-jin, CEO of Aptabio Therapeutics Inc.: “Concerns About the ADC ‘Red Ocean’… Big Pharma Companies Are Taking Notice of APTA-16”
“While most of the meetings at Bio USA are related to APX-115, there is also considerable interest in APTA-16, which is still in the preclinical stage. This is because global pharmaceutical companies …
Lifestyle
Vaxcell-Bio Therapeutics Set to Benefit Most from Revisions to the Advanced Biotechnology Act… O-Rim Rises on Expectations of a 'Big Deal' in China [Bio Spotlight]
On the 29th, the domestic pharmaceutical and life sciences sectors surged in tandem. The pharmaceutical sector index rose 9.52% compared to the previous trading day, with 143 out of 160 listed stocks …
Technology
Vaxcell, the Biggest Beneficiary of Regenerative Medicine Reform [K-Bio Pulse]
On the 29th, South Korea’s pharmaceutical and life sciences sectors posted strong gains. The pharmaceutical index rose 9.52%, with 143 of 160 listed companies advancing, while the life sciences index …
Venture
Lee Soo-jae, CEO of FNCT Biotech: "CSF3 Antibody Restores Stiffened Lungs to Their Original State... Discussing Technology Transfer with Big Pharma"
FNCT Biotech, a developer of new drugs for fibrosis and cancer treatment, has successfully completed its Series B funding round, raising its pre-IPO valuation to the 600억 won range. FNCT Biotech has i…
Technology
'The Warring States Period of Insulin Pumps'… CareMedi, EOFlow Co., Ltd., and CureStream Clash
The domestic patch-type insulin pump market is entering a competitive phase. CareMedi’s CareRevo—the second domestically produced insulin pump to receive approval in five years—was recently launched, …
Lifestyle
"Obesity Drugs That Cause Muscle Loss Have Their Limits"... DaewonPharmaceutical Bets on 'Quadruple-Action Agent' Beyond GLP-1
The obesity treatment market is rapidly evolving beyond simple weight loss, with competition now centered on innovations in dosage forms, administration schedules, and mechanisms of action. As the mar…
Lifestyle
Cellid Crashes in After-Hours Trading Following Phase 3 Failure...Shaperon Plummets 25% [K-bio pulse]
In the biopharmaceutical sector on Friday, Cellid’s stock surged on expectations for its vaccine clinical trial results, but the shares plunged by the daily limit in after-hours trading following news…
Lifestyle
Cellid Co., Ltd. Hits After-Hours Lower Circuit Breaker Following Phase 3 ‘Failure’… Shaperon Inc. Also Drops 25% [Bio Spotlight]
On the 26th, shares of Cellid Co., Ltd.(299660) surged significantly in the pharmaceutical and biotech sector amid expectations for the announcement of clinical trial results for a vaccine currently i…